In this study, we performed a genome-wide CRISPR-knockout screen for cytokine-independent survival of the MDS-L human cell line and identified FBXO11 as a potential tumor suppressor in MDS and secondary AML. This evidence concerns the gene FBXO11 and myelodysplastic syndrome.